Related Experiment Video

Updated: Apr 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell

Evgenii Shumilov1, Rebecca Wurm-Kuczera2, Joseph Kauer3

  • 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster.

Haematologica
|April 2, 2026
PubMed

Abstract:

Not available.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Experiment Videos

Last Updated: Apr 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

Articles linked to this work by shared authors, journal, and citation graph.

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis.

Blood advances·2026

Transplantation Strategies in Treatment of Primary Plasma Cell Leukemia in Germany-A Multi-Center Analysis.

European journal of haematology·2026

Overcoming access barriers in European CAR-T therapy: the role of decentralized manufacturing and the EASYGEN framework.

Cytotherapy·2026

Efficacy and safety of bridging therapy prior to CAR T-cell therapy in relapsed or refractory multiple myeloma.

Haematologica·2026

AI for prognostic assessment of diffuse large B-cell lymphoma using H&E whole-slide images.

HemaSphere·2026

A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.

Blood advances·2026

Prognostic significance of monotypic plasma cell infiltration of the bone marrow in patients with Waldenström macroglobulinemia.

Haematologica·2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

Haematologica·2026

Protecting sickle cell care during Ebola outbreaks.

Haematologica·2026

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Haematologica·2026

T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?

Haematologica·2026

Epidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era.

Haematologica·2026

Rhomboid protease RHBDL2 is a calcium-activated suppressor of EGFR signalling in keratinocytes.

Cellular and molecular life sciences : CMLS·2026

The Role of Ferroptosis Induced by Iron Overload in Osteoblast and Osteoclast Function.

Cell biology international·2026

Comparison of Uncovered and Covered Biliary SEMS for the Salvage of Obstructed SEMS: A Multicenter Retrospective Propensity Score-Weighted Study.

Journal of gastroenterology and hepatology·2026

Therapeutic Effects of WIN55,212-2 on Temporomandibular Joint Osteoarthritis in a Rat Model and Primary Temporomandibular Joint Condylar Chondrocytes.

Current medicinal chemistry·2026

Novel glutaminase-free l-asparaginase from Leuconostoc mesenteroides BN1: biochemical properties, molecular dynamics, and anticancer activity.

RSC advances·2026

Exploring Thyrotoxic Hypercalcaemia Through Two Cases: A Myriad of Uncertainties.

Case reports in endocrinology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us